熱門資訊> 正文
催化剂制药宣布到2026年2亿美元的股票回购计划
2025-10-01 20:31
- 觸媒製藥(CPRX) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Catalyst Pharmaceuticals (NASDAQ:CPRX) has authorized a new share repurchase program of up to $200M.
- The program allows for the repurchase of outstanding common stock between October 1, 2025, and December 31, 2026.
- Source: Press release
More on Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough
- Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
- Catalyst Pharmaceuticals settles lawsuit with Lupin
- Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
